5 ms·
Drug Shortages are Killing People
- Symmetry 13y agoSometimes I wonder if we wouldn't be better with real centrally planned drug production, even with all the negatives that implies. Then I remember that any system will inevitably result in mistakes, Congresswill respond to those mistakes with overbroad rules that restrict the planner, and we'll end up in an even worse situation. Well, I don't know. The recent FDA drug quality crackdown has probably saved a few lives at the cost of hundreds dieing from drug shortages. The problem is that the former number is much more squarely within the FDA's regulatory perview thant he later, giving them equal weight. Maybe if we had an organization equally responsible for both numbers we'd see better outcomes. ut then again, any beaurocratic boundaries will be unnatural at times, and you have to divide up departments somehow. I'm not sure any alternative organization wouldn't result in equally perverse outcomes. And on the gripping hand, regulators in Europe have somehow managed to avoid this problem entirely, so we should probably just copy what they're doing. But I suppose if that was realistic we would have copied the Swiss or Sinaporeans instead of passing the ACA.
- jjoonathan 13y ago> regulators in Europe have somehow managed to avoid this problem entirely > Maybe if we had an organization equally responsible for both numbers we'd see better outcomes. It's not a "somehow" -- you answered your own question! Add this to the long list of reasons why we should switch to single payer.
- Symmetry 13y agoExcept it's not actually the same bureaucratic entity that does both. The government may pay for health care but in many countries like France hospitals are still private businesses. I think the real difference more different levels of social trust in experts, parliamentary systems versus presidential systems, etc.
- _delirium 13y agoFrance has a hybrid system, where everyone is covered by the public system, but you can also choose to purchase care privately if you prefer. But most hospitals are publicly owned. The breakdown is about 60% public, 25% for-profit business, 15% nonprofit organization. Source for the numbers: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_rs_bds2&lang=en http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth...
- roc 13y ago> "Sometimes I wonder if we wouldn't be better with real centrally planned drug production" Or we could simply subsidize the modest overproduction of such critical, low-profit generics, selling or donating any surplus [1] not unlike what we do with food staples. This would encourage additional production, making any drops, for whatever reasons (regulatory, accidental, business-related) less of a systemic threat. In a world of imperfect solutions, I'll take that over additional regulatory bureaucracy or central planning. [1] I realize this isn't ideal and 'dumping' the surplus may well do more long-term harm in any communities we might help, short term, via donation. But that can be studied and determined. And, frankly, a robust public health system is important enough that even if we have to incinerate the surplus, subsidized overproduction may well be worth doing.
- refurb 13y agoWhat makes you think Europe has avoided the issue? They are having drug shortage problems of their own. http://www.policymed.com/2013/02/the-european-medicines-agency-mitigating-drug-shortages-in-europe.html http://www.policymed.com/2013/02/the-european-medicines-agen... This has nothing to do with the reimbursement system at all. Drug shortages are on the manufacturing side.
- rayiner 13y ago> The recent FDA drug quality crackdown has probably saved a few lives at the cost of hundreds dieing from drug shortages. We're playing with bigger numbers here. E.g. estimates were that Vioxx resulted in 90-140k additional cases of heart disease. The $5 billion paid in settlement of claims is a fraction of the actual damages, as settlements necessarily are.
- temphn 13y agoEven if you believe Nissen, the actual increase in risk was from .3 to .6%, and people who were denied Vioxx still want it back. An arthritis drug that vastly improves my life with probability 1 while maybe shortening it with some small probability is one that people should be free to choose, or not choose. You don't have the ethical right to dictate someone else's medical decisions.
- abtinf 13y agoThe problem is that drug production is centrally planned. Manufacturers must coordinate with the FDA for everything - when they are going to start production, how much they are going to produce, exactly how they will produce it, and so forth. This is a process that takes a significant amount of time. Thus, when there is a "shortage", a manufacturer can't simply increase the production run. Nor can others step in and also start producing in the near term. So people die. All shortages are, by definition, caused by the government.
- jotm 13y agoThat's what you get when some companies have a monopoly on selling drugs to your country's hospitals. There isn't an actual production shortage, it's just that the hospitals are bottlenecked by having one or just a couple of providers...
- mathattack 13y agoIs the bottleneck the drug companies, or the distributors?
- btian 13y agoThe FDA. Many drugs (especially low volume ones) cannot get approved for human use in the United States due to cost.
- mathattack 13y agoAhhh- that's why it's an issue that we don't accept the approval of other governments too.
- NoPiece 13y agoThat's not at all what the author of the blog has written previously. The FDA began to ramp up GMP rules and regulations under the new commissioner in 2010 and 2011 (see figure at left (N.B. this includes all warning letters not just GMP so it is just illustrative, AT added). In fact, the report indicates that FDA threats shut down some 30% of the manufacturing capacity at the big producers of generic injectables. The safety of these lines was not a large problem and could have been handled with a targeted approach but instead the FDA launched a sweep against all the major manufacturers at the same time. These problem have been exacerbated by a change in Medicare reimbursement rules and by the rise of GPOs (buying groups) which reduced the prices of generics. Thus, in response to the cut in capacity, firms have shifted production from less profitable generics to more profitable branded drugs, so we get shortages of generics rather than of branded drugs. - See more at: http://marginalrevolution.com/marginalrevolution/2012/06/drug-shortages-caused-by-the-fda.html#sthash.pTEWEO31.dpuf* http://marginalrevolution.com/marginalrevolution/2012/06/dru...
- kvb 13y agoThe Washingtonian article is very sad, but I'm not sure I buy Tabarrok's take on it. He once again harps on GMP regulations, but doesn't Europe have similar regulations? And the very first page of the Washingtonian article mentions a case where 9 patients died because a substitute PN was contaminated - to what extent would reducing oversight lead to even more such incidents? I'm open to the idea that FDA regulations are an issue but it hardly seems like that's the most pressing problem, given all of the other issues with our healthcare system.
- jjoonathan 13y ago> doesn't Europe have similar regulations The crucial difference is that Europe has primarily single-payer systems. They simply don't need a black market for legitimate drugs: even if you're poor, you can get them from the doctor. To be fair, the government won't pay for any drug -- it decides how much it is willing to pay based on efficacy, and some drugs get priced out (arguably because they deserve to get priced out).
- kvb 13y agoThat's certainly an important difference in general, but I don't see how it's relevant to this article. Here, the issue is not that people are priced out, it's that important, cheap drugs are underproduced.